X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GSK PHARMA ALKEM LABORATORIES/
GSK PHARMA
 
P/E (TTM) x - 60.9 - View Chart
P/BV x 6.4 11.4 56.4% View Chart
Dividend Yield % 0.7 2.5 26.7%  

Financials

 ALKEM LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GSK PHARMA
Mar-18
ALKEM LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5892,760 57.6%   
Low Rs1,2322,040 60.4%   
Sales per share (Unadj.) Rs417.5339.0 123.1%  
Earnings per share (Unadj.) Rs56.341.4 135.9%  
Cash flow per share (Unadj.) Rs64.745.9 141.0%  
Dividends per share (Unadj.) Rs12.7035.00 36.3%  
Dividend yield (eoy) %0.91.5 61.7%  
Book value per share (Unadj.) Rs292.9242.9 120.6%  
Shares outstanding (eoy) m119.5784.70 141.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.47.1 47.7%   
Avg P/E ratio x25.157.9 43.2%  
P/CF ratio (eoy) x21.852.3 41.7%  
Price / Book Value ratio x4.89.9 48.7%  
Dividend payout %22.684.5 26.7%   
Avg Mkt Cap Rs m168,653203,280 83.0%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1715,234 175.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,91528,715 173.8%  
Other income Rs m1,645545 301.6%   
Total revenues Rs m51,56129,260 176.2%   
Gross profit Rs m8,4825,059 167.7%  
Depreciation Rs m1,006380 264.7%   
Interest Rs m6712 33,530.0%   
Profit before tax Rs m8,4515,222 161.8%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m1,6061,892 84.9%   
Profit after tax Rs m6,7313,508 191.9%  
Gross profit margin %17.017.6 96.5%  
Effective tax rate %19.036.2 52.5%   
Net profit margin %13.512.2 110.4%  
BALANCE SHEET DATA
Current assets Rs m27,06221,815 124.1%   
Current liabilities Rs m15,32415,999 95.8%   
Net working cap to sales %23.520.3 116.1%  
Current ratio x1.81.4 129.5%  
Inventory Days Days6764 104.6%  
Debtors Days Days4119 220.9%  
Net fixed assets Rs m12,61012,475 101.1%   
Share capital Rs m239847 28.2%   
"Free" reserves Rs m34,49019,726 174.8%   
Net worth Rs m35,02720,573 170.3%   
Long term debt Rs m1,2126 20,193.3%   
Total assets Rs m54,38739,475 137.8%  
Interest coverage x13.62,612.0 0.5%   
Debt to equity ratio x00 11,860.8%  
Sales to assets ratio x0.90.7 126.2%   
Return on assets %13.68.9 153.1%  
Return on equity %19.217.1 112.7%  
Return on capital %24.926.2 94.7%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,563564 1,163.7%   
Fx outflow Rs m3,0127,429 40.5%   
Net fx Rs m3,552-6,865 -51.7%   
CASH FLOW
From Operations Rs m7,2594,728 153.5%  
From Investments Rs m1,864-1,042 -178.9%  
From Financial Activity Rs m-9,273-3,066 302.4%  
Net Cashflow Rs m-150620 -24.2%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 33.1 10.2 324.5%  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 102,036 67.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PANACEA BIOTECH  DISHMAN PHARMA  SUVEN LIFE  FRESENIUS KABI ONCO.  WOCKHARDT LTD.  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Dec 14, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - CIPLA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS